News

Cocrystal Pharma (COCP) – 3Q22 Reported – First Influenza Vaccine Data To Be Presented

Health
0 min read


Wednesday, November 16, 2022

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3Q22 Reported With Pipeline Update. Cocrystal reported a 3Q22 loss of $5.7 million or $0.70 per share. The product pipeline continues to make progress, with the first data from its influenza vaccine, CC-42344, scheduled for presentation in December. Two COVID-19 programs continue in preclinical studies, with an IND filing expected in 1Q23. The company ended the quarter with $42.1 million in cash.

Influenza Trial Data To Be Presented. Enrollment has been completed in the Phase 1 study for CC-42344 for seasonal and pandemic influenza. Safety and pharmacokinetic data is scheduled for presentation at the World Antiviral Congress in December 2022. The trial results will be submitted to regulatory authorities in the United Kingdom for a Phase 2a human challenge study to determine efficacy, expected to begin in 2H23.


Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comments

0
No comments yet...
Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.